Inflammatory Implantable Articles & Analysis: Older

1 news found

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society

"This release profile is exactly what I would want in an anti-inflammatory implant and the symptom improvement observed with LYR-210 is quite meaningful. ...

Oct. 4, 2021

ByLyra Therapeutics, Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you